AtriCure to Participate in Upcoming Investor Conferences
October 26 2020 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that the company will be
participating in two upcoming investor conferences.
AtriCure’s management team will be presenting at the Stifel
Healthcare Conference in a virtual setting on Wednesday, November
18, 2020, at 11:20 a.m. Eastern Time. Interested parties may access
a live and archived webcast of this event by visiting the
“Investors” section of the company’s website at
https://ir.atricure.com.
AtriCure management will be participating in one-on-one investor
meetings at the Canaccord MedTech and Diagnostics Forum in a
virtual setting on Thursday, November 19, 2020. Due to the format
of this event, no webcast will be available.
About AtriCure AtriCure, Inc. provides innovative
technologies for the treatment of Afib and related conditions. Afib
affects more than 33 million people worldwide. Electrophysiologists
and cardiothoracic surgeons around the globe use AtriCure
technologies for the treatment of Afib and reduction of Afib
related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval
for the treatment of persistent Afib. AtriCure’s AtriClip® Left
Atrial Appendage Exclusion System products are the most widely sold
LAA management devices worldwide. For more information, visit
AtriCure.com or follow us on Twitter @AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005115/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024